» Articles » PMID: 10455065

Matrix Metalloproteinase Inhibition During the Development of Congestive Heart Failure : Effects on Left Ventricular Dimensions and Function

Overview
Journal Circ Res
Date 1999 Aug 24
PMID 10455065
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

The development of congestive heart failure (CHF) is associated with left ventricle (LV) dilation and myocardial remodeling. The matrix metalloproteinases (MMPs) play a significant role in extracellular remodeling, and recent studies have demonstrated increased MMP expression and activity with CHF. Whether increased MMP activity directly contributes to the LV remodeling with CHF remains unknown. Accordingly, this study examined the effects of chronic MMP inhibition (MMPi) on LV size and function during the progression of CHF. Pigs were assigned to the following groups: (1) CHF, rapid pacing for 3 weeks at 240 bpm (n=12); (2) CHF/MMPi, rapid pacing and concomitant MMPi (PD166793, 20 mg/kg per day [n=10]), and (3) control (n=11). With pacing CHF, LV fractional shortening was reduced (19+/-1 versus 45+/-1%), and end-diastolic dimension increased (5.67+/-0.11 versus 3.55+/-0.05 cm), compared with baseline values (P<0.05). In the CHF/MMPi group, LV endocardial shortening increased (25+/-2%) and the end-diastolic dimension was reduced (4.92+/-0.17 cm) compared with CHF-only values (P<0.05). LV midwall shortening was reduced to a comparable degree in the CHF-only and CHF/MMPi groups. LV peak wall stress increased 3-fold with pacing CHF compared with controls and was significantly reduced in the CHF/MMPi group. LV myocardial stiffness was unchanged with CHF but was increased in the CHF/MMPi group. LV myocyte length was increased with pacing CHF compared with controls (180+/-3 versus 125+/-4 microm, P<0.05) and was reduced in the CHF/MMPi group (169+/-4 microm, P<0.05). Basal-state myocyte shortening velocity was reduced with pacing CHF compared with controls (33+/-2 versus 66+/-1 microm/s, P<0.05) and was unchanged in the CHF/MMPi group (31+/-2 microm/s). Using an ex vivo assay system, myocardial MMP activity was increased with pacing CHF and was reduced with chronic MMPi. In summary, concomitant MMPi with developing CHF limited LV dilation and reduced wall stress. These results suggest that increased myocardial MMP activity contributes to LV myocardial remodeling in developing CHF.

Citing Articles

Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes.

Kayvanpour E, Sedaghat-Hamedani F, Li D, Miersch T, Weis T, Hoefer I Biomolecules. 2024; 14(9).

PMID: 39334904 PMC: 11430616. DOI: 10.3390/biom14091137.


Enzyme-Responsive Nanoparticles for the Targeted Delivery of an MMP Inhibitor to Acute Myocardial Infarction.

Sullivan H, Liang Y, Worthington K, Luo C, Gianneschi N, Christman K Biomacromolecules. 2023; 24(11):4695-4704.

PMID: 37695847 PMC: 10646957. DOI: 10.1021/acs.biomac.3c00421.


Fatty Acid Amide Hydrolase Deficiency Is Associated with Deleterious Cardiac Effects after Myocardial Ischemia and Reperfusion in Mice.

Rajlic S, Surmann L, Zimmermann P, Weisheit C, Bindila L, Treede H Int J Mol Sci. 2022; 23(20).

PMID: 36293543 PMC: 9604059. DOI: 10.3390/ijms232012690.


Predominance of Heart Failure With Preserved Ejection Fraction in Postmenopausal Women: Intra- and Extra-Cardiomyocyte Maladaptive Alterations Scaffolded by Estrogen Deficiency.

Adekunle A, Adzika G, Mprah R, Ndzie Noah M, Adu-Amankwaah J, Rizvi R Front Cell Dev Biol. 2021; 9:685996.

PMID: 34660569 PMC: 8511782. DOI: 10.3389/fcell.2021.685996.


Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines.

Toro-Salazar O, Lee J, Zellars K, Perreault P, Mason K, Wang Z Cardiooncology. 2018; 4.

PMID: 29900007 PMC: 5995570. DOI: 10.1186/s40959-018-0030-5.